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Abstract
Background: Previous work has shown patients commonly misuse adrenaline au-
toinjectors (AAI). It is unclear whether this is due to inadequate training, or poor
device design. We undertook a prospective randomized controlled trial to evalu-
ate ability to administer adrenaline using different AAI devices.
Methods: We allocated mothers of food-allergic children prescribed an AAI for
the first time to Anapen or EpiPen using a computer-generated randomization
list, with optimal training according to manufacturer’s instructions. After one
year, participants were randomly allocated a new device (EpiPen, Anapen, new
EpiPen, JEXT or Auvi-Q), without device-specific training. We assessed ability to
deliver adrenaline using their AAI in a simulated anaphylaxis scenario six weeks
and one year after initial training, and following device switch. Primary outcome
was successful adrenaline administration at six weeks, assessed by an independent
expert. Secondary outcomes were success at one year, success after switching
device, and adverse events.
Results: We randomized 158 participants. At six weeks, 30 of 71 (42%) partici-
pants allocated to Anapen and 31 of 73 (43%) participants allocated to EpiPen
were successful – RR 1.00 (95% CI 0.68–1.46). Success rates at one year were
also similar, but digital injection was more common at one year with EpiPen (8/
59, 14%) than Anapen (0/51, 0%, P = 0.007). When switched to a new device
without specific training, success rates were higher with Auvi-Q (26/28, 93%) than
other devices (39/80, 49%; P < 0.001).
Conclusions: AAI device design is a major determinant of successful adrenaline
administration. Success rates were low with several devices, but were high using
the audio-prompt device Auvi-Q.
Anaphylaxis is life-threatening and increasingly reported (1, 2).
Prompt use of an adrenaline autoinjector (AAI) is the first-line
community treatment for anaphylaxis, and AAI sales have
increased in parallel with anaphylaxis hospitalizations (1, 3).
As emergency medical devices, AAIs should be simple to use;
however, cross-sectional surveys suggest that patients, their
parents and even healthcare practitioners are unable to use
commonly prescribed AAIs (4–7). Indeed, reports of accidental
digital injection using an AAI are common (8). These findings
may be due to a lack of adequate training, or to inherent flaws
in AAI device design. Prospective studies are required to estab-
lish whether AAI device design is adequate, and whether there
are important differences between AAIs that impact on ability
to successfully administer adrenaline for anaphylaxis. We
undertook a prospective randomized controlled trial to evalu-
ate the ability of mothers of food-allergic children, prescribed
and trained with an AAI for the first time, to successfully
administer adrenaline in a simulated anaphylaxis scenario. We
compared success rates in mothers allocated to different AAI
device designs.
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Materials and methods
Study design
We conducted a two-by-two factorial randomized controlled
trial to investigate the effect of adrenaline autoinjector (AAI)
device design on participants’ ability to administer adrenaline
in a simulated anaphylaxis scenario six weeks (primary out-
come) and one year after training, in mothers of food-allergic
children. Fathers or other carers were not included in this
study. After completion of the one-year assessment, we then
randomly reallocated participants to a further simulated ana-
phylaxis scenario using one of five different AAI device
designs, without specific training in the new AAI device, to
assess the safety of switching devices without further device-
specific training. Here, we report the outcomes of the AAI
trial main study (ISRCTN12504076) and the AAI device
switch study (ISRCTN29175528). We also simultaneously
evaluated a psychological intervention for reducing maternal
anxiety, which will be reported elsewhere.
Participants
Main study
Mothers of children aged 0–18, diagnosed with food allergy
by a paediatric allergist, and deemed to need an AAI as part
of their food allergy management were eligible for inclusion.
Exclusion criteria were inability to converse fluently in Eng-
lish or with a translator, child weight <7.5 kg, prior training
in an AAI device, and significant psychiatric problems such
as psychotic disorders.
Device switch study
Main Study participants who completed the outcome assess-
ment at one year (3 months) were eligible for inclusion in
the Device Switch Study. Exclusion criteria were training on
an alternative AAI device between randomization for the
Main Study and the one-year visit, and significant psycholog-
ical distress at the one-year scenario.
Study setting
Participants were recruited from a large specialist paediatric
allergy centre in an urban setting in London, UK, between
March 2011 and December 2012. Researchers invited moth-
ers of children with food allergy who were being prescribed
an AAI for the first time to participate. Written informed
consent was obtained prior to participation in any study pro-
cedures, and the study was approved by the West London
Research Ethics Committee (10/H0711/76).
Randomization, treatment allocation and masking
(i). First randomization (‘Main Study’). Treatment was allo-
cated using a computer-generated randomization list in
blocks of four, stratified by maternal anxiety (State Trait
Anxiety Inventory) score, generated by an independent statis-
tician (Imperial College London Statistical Advisory Service).
The randomization list was held by a clinical trials pharma-
cist – researchers notified the pharmacist after enrolling a
participant, and the pharmacist allocated treatment and dis-
pensed an AAI based on the randomization list.
(ii). Second randomization (‘Device Switch Study’). Treat-
ment was allocated using a computer-generated randomiza-
tion list stratified by ‘Main Study’ treatment allocation
(Anapen or EpiPen) and by success in AAI administration at
one year. The randomization list was generated by an inde-
pendent statistician (Imperial College London Statistical
Advisory Service) and held by a clinical trials pharmacist.
Researchers notified the pharmacist after enrolling a partici-
pant, and the pharmacist allocated a new AAI device for the
anaphylaxis scenario based on the randomization list.
It was not possible to mask clinicians, participants or out-
come assessors to AAI treatment allocation. To reduce ascer-
tainment bias, anaphylaxis scenario assessments were video
recorded and scored by a paediatric allergist independent of
the study sponsor, institution or investigators (TM).
Intervention
Main Study: participants were randomized to receive Ana-
penTM (Lincoln Medical, London, UK) or an EpiPenTM (My-
lan, Basking Ridge, NJ, USA) with standardized training.
Information included recognition of anaphylactic reactions,
management of such reactions including how and when to
use their AAI, and provision of a trainer AAI. The devices
are shown in Fig. S1. A researcher gave a practical demon-
stration of the use of the device and ensured participants
were able to demonstrate correct device technique before
leaving the training session. Written device-specific informa-
tion was provided, which was approved by the relevant
device manufacturer. All research staff were trained in ana-
phylaxis management through a national training programme
(Allergywise, Anaphylaxis Campaign, UK).
Device Switch Study: participants were randomly allocated
to be assessed using one of five alternative trainer AAI
devices. These were a new EpiPen device design (Mylan),
released during the course of the trial, JEXTTM (ALK-Abello,
Horsholm, Denmark), Anapen/EpiPen (whichever device the
participant had not been trained on during the Main Study),
or a device with audio prompts Auvi-QTM (Sanofi US, Kansas
City, MO, USA). The devices New EpiPen, JEXT and Auvi-
Q are shown in Fig. S2. Participants did not receive any spe-
cific training with the new device, but were asked to use it in
a simulated anaphylaxis scenario.
Outcome measures
Primary outcome measure was successful adrenaline adminis-
tration using a trainer AAI during a simulated anaphylaxis
scenario, six weeks after being trained for the first time (Main
Study). The four key steps needed for success were as follows:
removal of all safety caps, placement of correct end of the
device against the thigh, activation of device and holding
device in place for adrenaline delivery for ≥5 s. Where partici-
pants failed to deliver adrenaline, primary reason for failure
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was defined using a hierarchy of ‘Safety cap(s) removal > cor-
rect device positioning > device activation > held in place for
sufficient time’. The first step failed is the primary reason for
failure. Secondary outcomes included successful administra-
tion based on the same four key steps, but using the adrena-
line discharge time reported by the AAI manufacturer (3.2 s
Anapen, 1 s all other devices) instead of 5 s; successful
administration of adrenaline at one year; success after switch-
ing device; adverse events at each anaphylaxis scenario (digi-
tal injection) and participants’ confidence in how to use the
device at six weeks and one year (Main Study). The indepen-
dent allergist assessed participant actions using video record-
ings, with a device-specific scoring sheet, to decide whether
adrenaline would have been successfully delivered using 5-s
and device-specific criteria. Full details of the simulated ana-
phylaxis scenario are described in the Appendix S1.
Salivary stress response to simulated anaphylaxis
We also evaluate salivary cortisol and a-amylase levels in
participants before and after the one-year simulated anaphy-
laxis scenario (Main Study). For this analysis, samples were
taken immediately prior to the scenario, and 10, 20 and
30 min following the scenario. Saliva samples were collected
using cotton swabs (Salivettes; Sarstedt, Numbrecht, Ger-
many) and stored at 20°C until analysis. Salivary cortisol
and a-amylase levels were measured by a commercial com-
pany using published methodology (9).
Changes to study design
Anapen AAI (Lincoln Medical) was withdrawn from the UK
market on 23 May 2012. Those participants enrolled subse-
quently (n = 42) were therefore not randomly allocated to an
AAI device– all were allocated to EpiPen (Mylan). Partici-
pants who had already been allocated to Anapen were
invited for a six-week or one-year ( Device Switch) outcome
assessment as appropriate.
Statistical methods
Sample size calculation
Sample size for the Main Study was calculated on the basis
that 63% of participants would successfully deliver adrena-
line six weeks after training (6). With 86 participants in each
arm, we had 80% power at 5% two-sided significance using
chi-squared test to detect whether Anapen training results in
successful adrenaline delivery in 83% vs 63% for EpiPen.
Assuming 15% loss to follow-up at six weeks, we planned to
enrol 200 participants. Because of the unexpected withdrawal
of Anapen from the UK market part-way through the study,
we were able to recruit 79 patients in each arm (total 158).
Assuming 80% of Main Study participants are assessed at
one year, and 80% of these agree to participate in a second
anaphylaxis scenario (Device Switch Study), we planned to
undertake 128 s randomizations to undergo assessment with
a new AAI device (32 Auvi-Q; 32 New EpiPen; 32 JEXT; 32
Alternative device, i.e. Anapen/EpiPen). With 128 paired
comparisons, assuming a 50% success rate in the Main Study
one-year anaphylaxis scenario, the Device Switch Study had
80% power at 2-sided alpha 0.01 to detect whether 20% of
participants succeed in the Main Study one-year assessment
and fail in the Device Switch assessment, compared with 5%
failing in the Main Study one-year assessment/succeeding in
Device Switch.
Outcome analysis
We used chi-squared or Fisher’s exact test, and logistic
regression for adjusted analyses of binary outcomes, to calcu-
late odds ratios (OR) and 95% confidence intervals (95%
CI). We used Mann–Whitney U-test for continuous data
because they were non-normal as per Kolmogorov–Smirnov
test. We used bootstrapping to estimate 95% CI around
mean differences, and McNemar mid-p test for binary
matched-pair data (10). Primary analysis was conducted with
intention-to-treat population and secondary analysis with
per-protocol (PP) population. Assessment of successful
adrenaline delivery and adverse events was also made con-
temporaneously by the researcher. Due to good agreement
between researcher and independent assessor (TM) judgments
(kappa score for successful adrenaline delivery 0.88, six
weeks; 0.89, one year; 0.95, Device Switch Study), where the
primary outcome measure could not be determined from the
video recording, contemporaneous researcher assessment was
used (n = 9 cases for primary outcome assessment). PP analy-
sis at six weeks included participants nonrandomly allocated
to EpiPen, and excluded those who did not receive interven-
tion, did not attend six-week follow-up within 90 days of
treatment allocation, and whose outcomes were based on
contemporaneous researcher assessment. PP analysis at one
year also included participants nonrandomly allocated to
EpiPen, or not seen at one year (3 months), and whose out-
comes were based on contemporaneous researcher assess-
ment. All statistical analyses used SPSS v21.0 (IBM,
Armonk, NY, USA).
Results
We enrolled 158 randomized participants between 8 March
2011 and 23 May 2012. The 42 participants enrolled after 23
May 2012 could not be allocated to Anapen due to recall of
Anapen by the UK National Regulator, resulting in with-
drawal of Anapen from the UK market. These participants
were therefore nonrandomly allocated to EpiPen. The last
such participant was enrolled on 10 December 2012. Partici-
pant flow is shown in Fig. 1. Overall, 182 (91%) participants
and 145 (92%) randomized participants were assessed for the
primary outcome at six weeks, and 148 (74%) and 110 (70%)
at one year. Characteristics of study participants at enrol-
ment are shown in Table 1. The randomized groups were
similar, but there was a difference in personnel administering
AAI training in those participants nonrandomly allocated to
EpiPen, due to a staffing change part-way through the trial,
and improved asthma control in the nonrandomized group.
Those participants who failed to complete the study at one
year were more commonly not living with their partner, had
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Assessed for eligibility 
(n = 393)
Excluded  (n = 193)
Not eligible (n = 98)
Declined to participate (n = 95)
Anaphylaxis scenario at 6 weeks
71 completed scenario
5 lost to follow up
3 withdrew from study 
[1 bereavement; 2 no reason given]
ANAPEN (n = 79)
78 received intervention
1 failed to attend for training
Randomized (n = 158) Not randomized (n = 42)
Due to Anapen market recall
EPIPEN (n = 42)
40 received intervention
2 failed to attend for training
EPIPEN (n = 79)
78 received intervention
1 failed to attend for training
Enrolled (n = 200)
Anaphylaxis scenario at 6 weeks
74 completed scenario
5 lost to follow up
Anaphylaxis scenario at 6 weeks
37 completed scenario
1 lost to follow up
1 withdrew from study [time]
1 unable to contact
Anaphylaxis scenario at 1 year
51 completed scenario
19 not eligible [Anapen recall after 
randomisation]
1withdrew from study [no reason]
Anaphylaxis scenario at 1 year
59 completed scenario
10 lost to follow up
5 withdrew from study 
[3 time; 2 no reason given]
Anaphylaxis scenario at 1 year
38 completed scenario
1 contacted successfully, previously 
unable to contact
Device switch scenario
25 completed scenario
24 not eligible [completed 1 year
visit early, due to Anapen recall]
2 declined to complete scenario
Device switch scenario
52 completed scenario
4 not eligible [completed 1 year visit 
early, or trained on alternative 
device since randomisation]
3 declined to complete scenario 
Device switch scenario
31 completed scenario
7 not eligible [completed 1 year visit 
early, or trained on alternative 
device since randomisation ]
Figure 1 CONSORT flow diagram.
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a nonprofessional occupation, or were of nonwhite ethnicity
than those who completed the study; noncompleters also
more commonly had a child >25 kg (Tables S1 and S2).
Effect of AAI design on successful administration in a
simulated anaphylaxis scenario
The primary outcome successful AAI administration did not
differ between Anapen and EpiPen groups at six weeks or
one year, when either 5 s or device-specific delivery times
were used to assess success (Table 2; Fig. 2A). Participants
who completed the one-year visit were more likely to have
been successful at six weeks (Table S3). Imputation for miss-
ing data did not change the study findings (Table S4). There
was no significant difference between groups in the primary
reason for failure at six weeks, but there was a significant dif-
ference at one year where the Anapen group more commonly
failed to remove all safety caps, and the EpiPen group more
commonly used the incorrect end of the device. At one year
(but not at six weeks), the EpiPen group also had increased
frequency of digital injection (Fig. 2B). Similar findings were
seen in respect of primary reason for failure and digital injec-
tions in PP analysis. In PP analysis, there was also increased
overall success in the EpiPen group when using device-spe-
cific delivery times (but not a 5-second delivery time) and
EpiPen was held in place for longer than Anapen at six
weeks, but these differences were not significant in adjusted
analyses (Table S5).
Effect of AAI design on salivary stress response in a
simulated anaphylaxis scenario
There was an increase in salivary a-amylase (P < 0.001) but
not salivary cortisol (P = 0.37) level following the simulated
Table 1 Participant characteristics at baseline
Anapen (79) EpiPen (79) P
Not randomized
EpiPen (42) P
Maternal age (years) 36.4 (6.4) 35.6 (6.2) 0.48 36.2 (6.0) 0.86
Age left full-time education (years) 22.7 (5.3) 23.0 (6.3) 0.95 22.2 (3.8) 0.84
Living with partner 61 (79.2) 60 (76.9) 0.73 28 (75.7) 0.75
Professional occupation 37 (57.8) 35 (50.7) 0.41 17 (54.8) 0.94
Worked in a healthcare setting 11 (16.2) 17 (25.0) 0.20 8 (22.9) 0.77
Nonwhite ethnicity 48 (63.2) 46 (59.0) 0.60 22 (57.9) 0.72
Number of children in household
One child 31 (39.7) 31 (40.8) 23 (60.5)
Two children 33 (42.3) 27 (35.5) 11 (28.9)
Three or more children 14 (17.9) 18 (23.7) 0.58 4 (10.5) 0.07
Maternal state anxiety [STAI-1] 36.1 (11.5) 36.3 (11.3) 0.84 37.4 (12.6) 0.64
Child age (years) 4.5 (3.7) 3.5 (2.9) 0.06 3.8 (3.2) 0.88
Male child 47 (59.5) 50 (63.3) 25 (59.5)
Child weight ≥25 kg 18 (22.5) 12 (15.2) 0.22 6 (14.6) 0.52
No food allergies 2.6 (1.6) 3.2 (2.1) 0.05 2.4 (1.3) 0.17
Eczema in child 56 (75.7) 65 (86.7) 0.08 30 (76.9) 0.55
Eczema severity [POEM] 9.9 (7.3) 9.8 (7.7) 0.80 8.7 (5.5) 0.70
Asthma in child 21 (28.4) 18 (24.0) 0.54 5 (12.8) 0.08
Partially/Uncontrolled asthma 17 (23.0) 14 (18.7) 0.55 2 (5.1) 0.02
Allergic rhinitis in child 23 (31.5) 20 (26.7) 0.52 14 (36.8) 0.35
Moderate/Severe allergic rhinitis 21 (28.8) 18 (24.0) 0.51 12 (31.6) 0.52
History of anaphylaxis* 27 (35.1) 25 (32.1) 0.70 9 (23.1) 0.21
Anaphylaxis training officer
Researcher #1 13 (16.7) 13 (16.5) 0 (0.0)
Researcher #2 29 (37.2) 26 (32.9) 20 (51.3)
Researcher #3 36 (46.2) 40 (50.6) 0 (0.0)
Researcher #4 0 (0.0) 0 (0.0) 0.83 19 (48.7) <0.001
Randomized to psychological
intervention
40 (50.6) 39 (49.4) 0.87 22 (52.4) 0.78
Days since training at primary
outcome assessment
55.4 (17.7) 53.7 (19.4) 0.64 57.0 (19.7) 0.38
Continuous data are presented as mean (SD), categorical data as n (%). STAI, state trait anxiety inventory; POEM, patient-oriented eczema
measure.
*Anaphylaxis was defined according to NIH/NIAID guidance (2).
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anaphylaxis scenario at the one-year visit. The change in sali-
vary stress hormone levels did not differ significantly between
participants randomized to EpiPen vs Anapen for either a-
amylase (P = 0.34) or cortisol (P = 0.66).
Effect of AAI design on successful administration after
Device Switch without retraining
Successful AAI administration rates in the Device Switch
Scenario were comparable between participants originally
trained with EpiPen and those trained with Anapen using
either 5 s (P = 0.34) or device-specific delivery times
(P = 0.84), and these success rates did not differ overall,
from success rates using the device on which they had been
trained (Table 3). For example, success rates for participants
trained on EpiPen and switched to New EpiPen or JEXT
were 28/42 (67%) using EpiPen and 30/42 (71%) using the
new device (P = 0.51). However, successful AAI administra-
tion in the Device Switch Scenario differed according to the
specific device participants were randomly allocated to
(P < 0.001; Table S6). Participants allocated to Auvi-Q had
the highest success rate (26/28, 93% Auvi-Q vs 39/80, 49%
other devices; P < 0.001), whether they were previously
trained on Anapen or EpiPen, and this was higher than their
success rate in the preceding anaphylaxis scenario using the
device they had been trained to use (93% vs 57%;
P = 0.006).
There was a significant difference in success rate for partic-
ipants switched to a 2-cap device (Anapen) from a single-cap
device (EpiPen, New EpiPen, JEXT or Auvi-Q), or vice versa
(16/45, 36%), compared with participants switched between
different single-cap devices (49/63, 78%; P < 0.0001), and
those switched between Anapen and EpiPen had the lowest
success (15%; Fig. 3). This difference remained when Auvi-Q
was removed from analyses – 9/38 (24%) single-cap/2-cap
switch, 30/42 (71%) single-cap/single-cap switch (P < 0.0001)
– and was similar when device-specific adrenaline delivery
times were used (P < 0.0001; data not shown). Digital injec-
tion rates did not differ significantly between the 5 devices,
but were increased in participants originally trained with
Table 2 Ability to use an adrenaline autoinjector in participants randomly allocated to Anapen or EpiPen
Anapen (79) EpiPen (79) P RR (95% CI)
Primary outcome (six weeks)
Successful AAI administration (5-s criterion) 30 (42.3) 31 (42.5) 0.98 1.00 (0.68, 1.46)
Primary reason for failure
Failed to remove all safety caps 26 (36.6) 21 (28.8)
Used incorrect end of device 5 (7.0) 5 (6.8)
Device not activated 0 (0.0) 3 (4.1)
AAI applied for <5 s 10 (14.1) 13 (17.8) 0.27
Secondary Outcomes (six weeks)
Successful AAI administration (minimum discharge time) 32 (45.1) 40 (55.6) 0.21 0.81 (0.58, 1.13)
Adverse events (digital injection) 1 (1.4) 4 (5.4) 0.19 0.26 (0.03, 2.28)
Time device held in place (sec) 6.1 (4.7) 7.2 (5.1) 0.20 1.07 (0.64, 2.77)
Postscenario confidence (1–10) in using AAI device 7.4 (2.6) 7.5 (2.4) 0.90 0.15 (0.68, 0.94)
Area massaged after simulated injection 40 (56.3) 40 (54.1) 0.78 1.04 (0.78, 1.40)
Device applied to correct anatomical position 60 (84.5) 66 (89.2) 0.40 0.95 (0.83, 1.08)
Child held in correct position 48 (67.6) 51 (68.9) 0.87 0.98 (0.79, 1.23)
Emergency services called 57 (80.3) 54 (73.0) 0.30 1.10 (0.92, 1.32)
Secondary Outcomes (one year)
Successful AAI administration (5-s criterion) 28 (54.9) 35 (59.3) 0.64 0.93 (0.67, 1.28)
Primary reason for failure
Failed to remove all safety caps 17 (33.3) 6 (10.2)
Used incorrect end of device 0 (0.0) 10 (16.9)
Device not activated 0 (0.0) 1 (1.7)
AAI applied for <5 s 6 (11.8) 7 (11.9) <0.001
Successful AAI administration (minimum discharge time) 30 (58.8) 42 (71.2) 0.17 0.83 (0.62, 1.10)
Adverse events (digital injection) 0 (0.0) 8 (13.6) 0.007 –
Time device held in place (sec) 7.1 (4.4) 8.5 (4.4) 0.15 1.40 (0.24, 3.08)
Postscenario confidence (1–10) in using AAI device 7.2 (2.1) 7.0 (2.6) 0.99 0.17 (1.01, 0.73)
Area massaged after simulated injection 41 (80.4) 37 (62.7) 0.04 1.28 (1.01, 1.63)
Device applied to correct anatomical position 49 (96.1) 58 (98.3) 0.60 0.977 (0.92, 1.04)
Child held in correct position 43 (84.3) 47 (79.7) 0.53 1.06 (0.89, 1.26)
Emergency services called 44 (86.3) 54 (93.1) 0.34 0.93 (0.81, 1.06)
Continuous data are mean (SD) and mean difference (95% CI), categorical data as n (%). AAI, adrenaline autoinjector.
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Anapen when switched to a different device, compared with
those originally trained with EpiPen (P = 0.01). The effect of
a Device Switch in the community, with retraining, on suc-
cessful AAI administration is described in the Appendix S1.
Discussion
In this prospective randomized controlled trial in mothers of
food-allergic children, less than half of participants were able
to administer adrenaline using a commonly prescribed AAI
device in a simulated anaphylaxis scenario, six weeks follow-
ing optimal training. When participants were switched to
alternative but similar devices without retraining, success
rates did not improve, but when switched to an audio-
prompt device Auvi-Q, success rates were high. In contrast
to previous work, our data clearly demonstrate that AAI
device design, not simply AAI training, is critical for success-
ful adrenaline delivery in an emergency scenario. Our data
also highlight important areas for improvement in the design
of some currently available AAI devices. This information is
especially timely given the ongoing European Medicines
Agency Section 31 review of AAI devices, triggered by the
death of a young patient treated for anaphylaxis with an
AAI [EMA/242569/2014 (11)].
Previous cross-sectional surveys have found patients and
healthcare practitioners are commonly unable to administer
adrenaline using an AAI trainer (4–7). However, such studies
have not been able to determine whether the high failure rate
is due to inadequate training or inherent issues with device
design. In support of a role for training, a recent US study
found that 16% of patients previously prescribed an AAI
could perform all steps correctly, but success rates increased
immediately after a formal training session, and this increase
persisted 1 year later (12). Using a more rigorous simulated
anaphylaxis scenario and prospective study design, we have
clearly shown that device design is a critical factor in success-
ful AAI use and that success rates using commonly pre-
scribed devices are worryingly low even 6 weeks following
training. In our study, all participants were optimally trained
and were able to successfully administer adrenaline using a
trainer AAI at the end of the initial training session. Failure
0
5
10
15
20
6 weeks 12 months
%
Anapen EpiPen
0
20
40
60
80
100
6 weeks 12 months
%
Anapen EpiPen
P = 0.007
P = 0.19
P = 0.64P = 0.98
Successful EAI administration Adverse events (digital injection)
A B
Figure 2 Main Study Outcomes. Rates of successful adrenaline administration (A) and digital injection (B) in participants randomly allocated
to Anapen or EpiPen at 6 weeks and one year following initial training.
Table 3 Ability to use a different adrenaline autoinjector in participants trained to use Anapen or EpiPen
Prior Anapen training (25)
n (%)
Prior EpiPen training (83)
n (%) Total (108) n (%)
Anapen
New
device P EpiPen
New
device P
Original
device
New
device P
Successful AAI administration (5-s criterion) 14 (56.0) 13 (52.0) 0.79 54 (65.1) 52 (62.7) 0.74 68 (63.0) 65 (60.2) 0.67
Successful AAI administration (minimum
discharge time)
14 (56.0) 16 (64.0) 0.55 65 (78.3) 55 (66.3) 0.08 79 (73.1) 71 (65.7) 0.22
Adverse events (digital injection) 0 (0.0) 3 (12.0) – 9 (10.8) 0 (0.0) – 9 (8.3) 3 (2.8) 0.60
0
20
40
60
80
100
Anapen/Epipen New EpiPen JEXT Auvi-Q
%
Anapen
EpiPen
P < 0.001
Figure 3 Device Switch Study Outcome. Rates of successful
adrenaline administration in participants who had Anapen (blue) or
old-style EpiPen (red) for a year and were then randomly allocated
to undergo an anaphylaxis scenario using a new device, without
training.
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to remove safety cap(s), use of the incorrect end of the device
and holding the device in place for insufficient time were the
most common primary reasons for failure, suggesting these
are important areas for AAI device developers to focus on.
As the number of different AAI designs has increased,
Device Switches have become a significant clinical issue. To
our knowledge, this is the first study to directly address the
safety of Device Switches. We found successful adrenaline
administration rates were similar where the new device was
similar to the old one. However, success rates dropped after
switching between a one-cap and a two-cap device without
training and increased after switching to the audio-prompt
device Auvi-Q. These data suggest that care must be taken
when a patient’s AAI device is changed to an alternative
design.
Strengths of our study include the prospective design in a
representative clinic population, use of a simulated anaphy-
laxis scenario for assessments, which induced a significant
stress response in participants, and outcome classification by
an independent expert. AAI training was undertaken under
optimal conditions, and all study participants demonstrated
successful adrenaline administration using a trainer device
prior to leaving their initial training session. Statistical power
was limited by withdrawal of Anapen part-way through the
trial, meaning 21% of participants were nonrandomly allo-
cated to an AAI device and some participants were not eligi-
ble for secondary outcome assessments. However, the study
findings were clear-cut, and robust in per-protocol analysis
and adjusted analysis and after imputation for missing data.
Our findings in a representative UK paediatric allergy
clinic population may not be generalizable to other settings –
in particular, the AAI training in some settings may be more
limited than that received in the setting of a clinical trial,
where staff were recently well trained, and participants were
given as much time as they needed to ensure AAI training
was complete and understood. For example, a recent survey
of community pharmacists in Australia found that only 65%
could correctly demonstrate to a ‘patient’ how to use their
AAI (13). Mothers of food-allergic children may have differ-
ent performance characteristics in an emergency scenario to
other patient groups at risk of anaphylaxis, so our findings
cannot be generalized to all groups. Food allergy is however
the commonest cause of anaphylaxis and is most prevalent
among young children where mothers are often the primary
caregiver, and fatal food anaphylaxis commonly occurs in
the home environment – thus, mothers of food-allergic chil-
dren represent an important group for effective AAI training
(1, 14). Finally, the availability of AAI devices varies consid-
erably worldwide, with no AAIs marketed in some countries,
and restricted choice of AAI in many areas. Our data will
however inform treatment decisions in settings where more
than one AAI device is available.
Our data provide the most conclusive evidence to date that
there are significant design issues in some current AAI
devices. Given that AAIs are associated with significant
adverse events (8), that the evidence base for adrenaline in
treating human anaphylaxis is weak (15), and that new non-
injectable modes of adrenaline delivery may soon become
available (16), we suggest that the role of different AAI
device designs in clinical practice should be carefully evalu-
ated within existing reviews of this area (11). In contrast, the
high rate of successful adrenaline administration which we
found when participants used the audio-prompt device Auvi-
Q, in a stressful anaphylaxis scenario and without prior
device-specific training, suggests that Auvi-Q is an important
advance in AAI device design and may even be suitable for
bystander use in public areas such as schools (17). Thus,
Auvi-Q or other audio-prompt devices may play a similar
role to automated external defibrillators with audiovisual
cues, which are currently used for bystander treatment of car-
diac arrest (18).
In summary, we have shown in a prospective randomized
controlled trial that successful adrenaline administration rates
using Anapen and EpiPen are low during simulated anaphy-
laxis, and EpiPen use under stressful conditions carries a sig-
nificant risk of digital injection. Over 90% of participants
were able to successfully administer adrenaline using Auvi-Q
without receiving device-specific training, suggesting that
AAI device design is critical to successful anaphylaxis man-
agement and this should be carefully assessed in the current
European Medicines Agency AAI review.
Acknowledgments
We are grateful to Bernard North from the Imperial College
London Statistical Advisory Service and to Andrew Clark
from Cambridge University for advice on study design, to
MEDA pharmaceuticals, ALK-Abello, Lincoln Medical and
Intelliject for review of training materials, provision of train-
ing devices, and/or review of outcome assessment scoring
sheets.
Funding
The authors were supported by the National Institute for
Health Research (NIHR) Imperial Biomedical Research Cen-
tre, and the MRC-Asthma UK Centre in Allergic Mecha-
nisms of Asthma. P. J. Turner is in receipt of a Clinician
Scientist award from the UK Medical Research Council. This
study was supported by research grants from Lincoln Medi-
cal and the NIHR Comprehensive Research Network.
Role of funders
The funders had no role in study design; in the collection,
analysis, and interpretation of data; in the writing of the
report; or in the decision to submit the article for publica-
tion.
Role of researchers
The researchers are fully independent of the funding bodies
which supported this trial. All authors, external and internal,
had full access to all of the data (including statistical reports
and tables) in the study and can take responsibility for the
integrity of the data and the accuracy of the data analysis.
Allergy 70 (2015) 855–863 © 2015 The Authors. Allergy Published by John Wiley & Sons Ltd862
AAI design and anaphylaxis treatment Umasunthar et al.
Conflict of interest
All authors have completed the Unified Competing Interest
form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare that JOW
is a trustee of the Anaphylaxis Campaign, and JOW and RJB
have received research funding from the UK Food Standards
Agency. The authors report no other relationships or activities
that could appear to have influenced the submitted work.
Author contributions
RJB conceived the study, secured funding for the trial and
wrote the final version of the manuscript. JOW, CG, MH and
HEC contributed to study design. TU wrote the study protocol
and other clinical trials materials, supervised by RJB, secured
regulatory approvals, set up the study and wrote the first draft
of the manuscript. AP, HH, KP and CP recruited and trained
participants and completed study assessments. TM performed
independent assessments of videotaped simulated anaphylaxis
scenarios for primary outcome evaluation. AP, RJB and JS
wrote the statistical analysis plan. JS undertook all statistical
analyses. All authors contributed to the interpretation of data
analyses and drafting of the final manuscript.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Epinephrine auto-injector devices used in the
Main Study.
Figure S2. Additional epinephrine auto-injector devices
used in the Device Switch Study.
Appendix S1. Supplementary Methods and Results.
Table S1. Participant characteristics at baseline, for rando-
mised patients who did or did not complete outcome assess-
ments at 6 weeks.
Table S2. Participant characteristics at baseline, for rando-
mised patients who did or did not complete outcome assess-
ments at one year.
Table S3. Six-week outcomes for randomised patients who
did or did not complete a one year outcome assessment.
Table S4. Results of imputation for missing data, for
patients randomly allocated to Anapen or Epipen.
Table S5. Ability to use their epinephrine autoinjector in
participants allocated to Anapen or Epipen – Per Protocol
analysis.
Table S6. Ability to use different devices in participants
trained to use Anapen or EpiPen.
References
1. Turner PJ, Gowland MH, Sharma V, Ierodi-
akonou D, Harper N, Garcez T et al. Increase
in anaphylaxis-related hospitalizations but
no increase in fatalities: an analysis of
United Kingdom national anaphylaxis data.
J Allergy Clin Immunol 2015;135:956–963.
2. Sampson HA, Munoz-Furlong A, Campbell
RL, Adkinson NF Jr, Bock SA, Branum A
et al. Second symposium on the definition
and management of anaphylaxis: summary
report–Second National Institute of Allergy
and Infectious Disease/Food Allergy and
Anaphylaxis Network symposium. J Allergy
Clin Immunol 2006;117:391–397.
3. Muraro A, Roberts G, Worm M, Bilo MB,
Brockow K, Fernandez Rivas M et al. Ana-
phylaxis: guidelines from the European
Academy of Allergy and Clinical Immunol-
ogy. Allergy 2014;69:1026–1045.
4. Gold MS, Sainsbury R. First aid anaphy-
laxis management in children who were pre-
scribed an adrenaline autoinjector device
(EpiPen). J Allergy Clin Immunol
2000;106:171–176.
5. Sicherer SH, Forman JA, Noone SA. Use
assessment of self-administered adrenaline
among food-allergic children and pediatri-
cians. Pediatrics 2000;105:359–362.
6. Mehr S, Robinson M, Tang M. Doctor–how
do I use my EpiPen? Pediatr Allergy Immu-
nol 2007;18:448–452.
7. Noimark L, Wales J, Du Toit G, Pastacaldi
C, Haddad D, Gardner J et al. The use of
adrenaline autoinjectors by children and
teenagers. Clin Exp Allergy 2012;42:284–292.
8. Simons FE, Edwards ES, Read EJ Jr, Clark S,
Liebelt EL. Voluntarily reported unintentional
injections from adrenaline auto-injectors.
J Allergy Clin Immunol 2010;125:419–423.
9. Strahler J, Mueller A, Rosenloecher F,
Kirschbaum C, Rohleder N. Salivary
alpha-amylase stress reactivity across differ-
ent age groups. Psychophysiology 2010;47:
587–595.
10. Fagerland MW, Lydersen S, Laake P. The
McNemar test for binary matched-pairs
data: mid-p and asymptotic are better than
exact conditional. BMC Med Res Methodol
2013;13:91.
11. European Medicines Agency. Adrenaline
auto-injectors 2014. http://www.ema.euro-
pa.eu/ema/index.jsp?curl=pages/medicines/
human/referrals/Adrenaline_auto_injectors/
human_refer-
ral_000367.jsp&mid=WC0b01ac05805c516f.
12. Sicherer SH, Vargas PA, Groetch ME,
Christie L, Carlisle SK, Noone S et al.
Development and validation of educational
materials for food allergy. J Pediatr
2012;160:651–656.
13. Salter SM, Loh R, Sanfilippo FM, Clifford
RM. Demonstration of adrenaline autoinjec-
tors (EpiPen and Anapen) by pharmacists in
a randomised, simulated patient assessment:
acceptable, but room for improvement.
Allergy Asthma Clin Immunol 2014;10:49.
14. Osborne NJ, Koplin JJ, Martin PE, Gurrin
LC, Lowe AJ, Matheson MC et al. Preva-
lence of challenge-proven IgE-mediated
food allergy using population-based sam-
pling and predetermined challenge criteria
in infants. J Allergy Clin Immunol 2011;127:
668–676.
15. Dhami S, Panesar SS, Roberts G, Muraro
A, Worm M, Bilo MB et al. Management of
anaphylaxis: a systematic review. Allergy
2014;69:168–175.
16. Rawas-Qalaji M, Rachid O, Mendez BA,
Losada A, Simons FE, Simons KJ. Adrena-
line (adrenaline) microcrystal sublingual tab-
let formulation: enhanced absorption in a
preclinical model. J Pharm Pharmacol
2015;67:20–25.
17. School Access to Emergency Adrenaline Act
Public Law 113-48. 127 STAT 575 http://
www.gpo.gov/fdsys/pkg/PLAW-113publ48/
pdf/PLAW-113publ48.pdf: US government
Printing Office, 2013.
18. Caffrey SL, Willoughby PJ, Pepe PE, Becker
LB. Public use of automated external defi-
brillators. N Engl J Med 2000;347:1242–
1247.
Allergy 70 (2015) 855–863 © 2015 The Authors. Allergy Published by John Wiley & Sons Ltd 863
Umasunthar et al. AAI design and anaphylaxis treatment
